The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma

详细信息    查看全文

• 作者：Arihiro Aihara ; Shinji Tanaka ; Mahmut Yasen ; Satoshi Matsumura ; Yusuke Mitsunori ; Ayano Murakata ; Norio Noguchi ; Atsushi Kudo ; Noriaki Nakamura ; Koji Ito ; Shigeki Arii
• 关键词：Hepatocellular carcinoma ; Aurora B kinase ; AZD1152 ; Orthotopic model ; Molecular-targeted agent
• 刊名：Journal of Hepatology
• 出版年：2010
• 出版时间：January 2010
• 年：2010
• 卷：52
• 期：1
• 页码：63-71
• 全文大小：1665 K

文摘

Background & Aims

We previously identified that high Aurora B expression was associated with hepatocellular carcinoma (HCC) recurrence due to tumor dissemination. In this preclinical study, a novel inhibitor of Aurora B kinase was evaluated as a treatment for human HCC.

Methods

AZD1152 is a selective inhibitor of Aurora B kinase. Twelve human HCC cell lines were analyzed for Aurora B kinase expression and the in vitro effects of AZD1152. The in vivo effects of AZD1152 were analyzed in a subcutaneous xenograft model and a novel orthotopic liver xenograft model.

Results

Aurora B kinase expression varied among the human HCC cell lines and was found to correlate with inhibition of cell proliferation, accumulation of 4N DNA, and the proportion of polyploid cells following administration of AZD1152-hydroxyquinazoline-pyrazol-anilide (AZD1152-HQPA). AZD1152-HQPA suppressed histone H3 phosphorylation and induced cell death in a dose-dependent manner. Growth of subcutaneous human HCC xenografts was inhibited by AZD1152 administration. In an orthotopic hepatoma model, treatment with AZD1152 significantly decelerated tumor growth and increased survival. Pharmacobiological analysis revealed that AZD1152 induced the rapid suppression of phosphohistone H3, followed by cellular apoptosis in the liver tumors but not in the normal tissues of the orthotopic models.

Conclusions

Our preclinical studies indicate that AZD1152 is a promising novel therapeutic approach for the treatment of HCC.